These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38419787)

  • 1. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
    Hadjadj S; Cooper ME; Steubl D; Petrini M; Hantel S; Mattheus M; Wanner C; Thomas MC
    Kidney Med; 2024 Mar; 6(3):100783. PubMed ID: 38419787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
    McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH;
    J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):51-60. PubMed ID: 38061372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
    Kraus BJ; Weir MR; Bakris GL; Mattheus M; Cherney DZI; Sattar N; Heerspink HJL; Ritter I; von Eynatten M; Zinman B; Inzucchi SE; Wanner C; Koitka-Weber A
    Kidney Int; 2021 Mar; 99(3):750-762. PubMed ID: 33181154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
    Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
    JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
    J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.
    Perkovic V; Koitka-Weber A; Cooper ME; Schernthaner G; Pfarr E; Woerle HJ; von Eynatten M; Wanner C
    Nephrol Dial Transplant; 2020 Dec; 35(12):2103-2111. PubMed ID: 31495881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.
    Ruggenenti P; Kraus BJ; Inzucchi SE; Zinman B; Hantel S; Mattheus M; von Eynatten M; Remuzzi G; Koitka-Weber A; Wanner C
    EClinicalMedicine; 2022 Jan; 43():101240. PubMed ID: 35005582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.